Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05845450 | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | recruiting | Phase 2 | 197 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05884333 | Cord Blood Transplant in Adults With Blood Cancers | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06049290 |
| A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma |
| recruiting |
| Phase 1 / Phase 2 |
| 342 |
| Nanjing Leads Biolabs Co.,LtdINDUSTRY |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT06200155 | Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06229912 | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | recruiting | Phase 2 | 60 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06517017 | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma(UltraFrailMM) | recruiting | Phase 2 | 40 | University of UtahOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL(SOUNDTRACK-B) | recruiting | Phase 2 | 270 | AstraZenecaINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT06566742 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | BeOne MedicinesINDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06797999 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma(ADCElerate1) | recruiting | Phase 1 / Phase 2 | 270 | Adcendo ApSINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 154 | Debiopharm International SAINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061951 | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07222488 | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | recruiting | Phase 1 / Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT07381764 | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"(ROMANCE - GOIM) | recruiting | Phase 2 | 150 | Gruppo Oncologico Italia MeridionaleOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT07815223 | A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC | recruiting | Phase 2 | 20 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815522 | Abiraterone With Dalpiciclib in Salivary Gland Carcinoma | recruiting | Phase 2 | 36 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma(HARMONi-GU1) | recruiting | Phase 2 / Phase 3 | 800 | Summit TherapeuticsINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03104491 | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 44 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer(Morpheus-panBC) | recruiting | Phase 1 / Phase 2 | 1,132 | Hoffmann-La RocheINDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1) | recruiting | Phase 2 | 99 | Genentech, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04864054 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC(ARYA-3) | recruiting | Phase 1 / Phase 2 | 60 | Eureka Therapeutics Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04865887 | Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | recruiting | Phase 2 | 35 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05052957 | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)(hSTAR GBM) | recruiting | Phase 2 | 16 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05546827 | Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05762536 | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC(DAROTAXEL) | recruiting | Phase 2 | 245 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | recruiting | Phase 2 | 48 | University of California, San FranciscoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06100705 | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | recruiting | Phase 2 | 26 | Yale UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06345079 | Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours(STOPNET) | recruiting | Phase 2 | 78 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06563947 | Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy | recruiting | Phase 2 | 30 | Xu Yong, MDOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 / Phase 3 | 216 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.(ABC-R) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07766018 | A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 70 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 11, 2026source: clinicaltrials